Guardant Health: Competitors Are Trading At Cheaper Valuations [Seeking Alpha]
Guardant Health, Inc. (GH)
Last guardant health, inc. earnings: 2/24 04:03 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
Guardant Health: Competitors Are Trading At Cheaper Valuations Summary Guardant Health Inc. focuses on precision oncology. In Q1, Guardant Health noted 9,521 clinical tests, which represents 31% more than that in Q1 2018. The revenue is growing at a fast pace. The total quarterly revenue increased by 119% y/y amounting to $36.6 million. The management noted the publication of the NILE study in the most recent earnings call. In the tests that included 282 patients, the company proved that using cfDNA increased detection by 48%. Market participants should understand that the risk is significant. If the company is not successful in selling the new early detection program, the total valuation should decline. After the IPO, Guardant Health ( GH Business, Solutions And Partners Founded in 2011, Guardant Health Inc. focuses on precision oncology. Source: Company’s Website The company sells two biopsy tests, called Guardant360 and GuardantOMNI. Furthermore, it is developing tests for its earl
Show less
Read more
Impact Snapshot
Event Time:
GH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GH alerts
High impacting Guardant Health, Inc. news events
Weekly update
A roundup of the hottest topics
GH
News
- Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024Business Wire
- Guardant Health, Inc. (NASDAQ: GH) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- Guardant Health, Inc. (NASDAQ: GH) had its "neutral" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Plug and Play Welcomes First Silicon Valley Startup Batches of 2024 [Yahoo! Finance]Yahoo! Finance
- Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
GH
Earnings
- 2/22/24 - Beat
GH
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- GH's page on the SEC website